Advertisement

Risk-Adjusted Strategies in Post-Treatment Surveillance of Well-Differentiated Thyroid Carcinoma

  • Erik S. Venos
  • Vicky M. Parkins
Part of the Head and Neck Cancer Clinics book series (HNCC)

Abstract

Well-differentiated thyroid cancer (WDTC) is unique among solid-organ tumours—while its incidence is increasing, its mortality, in the majority of cases, is low. In addition, significant changes have been made in conventional management paradigms, ranging from the initial surgical approach to the increasingly restrictive use of radioactive iodine. The result is that post-surgical management of patients with WDTC is becoming increasingly individualized and based on the risk of recurrence and the morbidity and mortality of WDTC therapies. This chapter reviews this risk-adapted management.

Keywords

Thyroid Cancer Papillary Thyroid Carcinoma Total Thyroidectomy Medullary Thyroid Cancer Extrathyroidal Extension 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167214.Google Scholar
  2. 2.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Tuttle RM, Tala H, Shah J, et al. Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. Thyroid. 2010;20:1341–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Tuttle RM, Leboeuf R. Follow up approaches in thyroid cancer: a risk adapted paradigm. Endocrinol Metab Clin North Am. 2008;37:419–35.PubMedCrossRefGoogle Scholar
  5. 5.
    Tuttle RM, Rondeau G, Lee NY. A risk-adapted approach to the use of radioactive iodine and external beam radiation in the treatment of well-differentiated thyroid cancer. Cancer Control. 2011;18:89–95.PubMedGoogle Scholar
  6. 6.
    Greene FL, Page DL, Fleming ID, et al. AJCC cancer staging handbook. 6th ed. New York: Springer; 2002.CrossRefGoogle Scholar
  7. 7.
    Jonklaas J, Nogueras-Gonzalez G, Munsell M, et al. The impact of age and gender on papillary thyroid cancer survival. J Clin Endocrinol Metab. 2012;97:E878–87.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Lang BH, Lo CY, Chan WF, et al. Staging systems for papillary thyroid carcinoma: a review and comparison. Ann Surg. 2007;245:366–78.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050–7; discussion 1057–8.PubMedGoogle Scholar
  10. 10.
    Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid. 2012;22:884–9.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Buffet C, Golmard JL, Hoang C, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma. Eur J Endocrinol. 2012;167:267–75.PubMedGoogle Scholar
  12. 12.
    Roti E, degli Uberti EC, Bondanelli M, et al. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;159:659–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Pazaitou-Panayiotou K, Capezzone M, Pacini F. Clinical features and therapeutic implication of papillary thyroid microcarcinoma. Thyroid. 2007;17:1085–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Lin HW, Bhattacharyya N. Survival impact of treatment options for papillary microcarcinoma of the thyroid. Laryngoscope. 2009;119:1983–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Bilimoria KY, Bentrem DJ, Ko CY, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375–84.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Vaisman F, Shaha A, Fish S, et al. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. Clin Endocrinol (Oxf). 2011;75:112–9.CrossRefGoogle Scholar
  17. 17.
    Nixon IJ, Ganly I, Patel SG, et al. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. Surgery. 2012;151:571–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Sacks W, Fung CH, Chang JT, et al. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. Thyroid. 2010;20:1235–45.PubMedCrossRefGoogle Scholar
  19. 19.
    Haymart MR, Banerjee M, Stewart AK, et al. Use of radioactive iodine for thyroid cancer. JAMA. 2011;306:721–8.PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Schvartz C, Bonnetain F, Dabakuyo S, et al. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients. J Clin Endocrinol Metab. 2012;97:1526–35.PubMedCrossRefGoogle Scholar
  21. 21.
    Iyer NG, Morris LGT, Tuttle RM, et al. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer. 2011;117:4439–46.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Brown AP, Chen J, Hitchcock YJ, et al. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab. 2008;93:504–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Mallick U, Harmer C, Yap B, et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med. 2012;366:1674–85.PubMedCrossRefGoogle Scholar
  24. 24.
    Schlumberger M, Catargi B, Borget I, et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med. 2012;366:1663–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Orlov S, Freeman JL, Walfish PG. Radioiodine ablation in low-risk thyroid cancer. N Engl J Med. 2012;367:672; author reply 673–5.PubMedCrossRefGoogle Scholar
  26. 26.
    Hugo J, Robenshtok E, Grewal R, et al. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence. Thyroid. 2012;22:1007–15.PubMedCrossRefGoogle Scholar
  27. 27.
    Tuttle RM, Lopez N, Leboeuf R, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 2010;20:257–63.PubMedCrossRefGoogle Scholar
  28. 28.
    Alexander EK, Larsen PR. Radioiodine for thyroid cancer—is less more? N Engl J Med. 2012;366:1732–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Mernagh P. Cost-effectiveness of using recombinant human TSH prior to radioiodine ablation for thyroid cancer, compared with treating patients in a hypothyroid state: The German perspective. Eur J Endocrinol. 2006;155:405–14.PubMedCrossRefGoogle Scholar
  30. 30.
    Wang TS, Cheung K, Mehta P, et al. To stimulate or withdraw? A cost-utility analysis of recombinant human thyrotropin versus thyroxine withdrawal for radioiodine ablation in patients with low-risk differentiated thyroid cancer in the United States. J Clin Endocrinol Metab. 2010;95:1672–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91:926–32.PubMedCrossRefGoogle Scholar
  32. 32.
    Randolph G, Duh QY, Heller KS, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension ATA surgical affairs committee’s taskforce on thyroid cancer nodal surgery. Thyroid. 2012;10.Google Scholar
  33. 33.
    Hay ID, Thompson GB, Grant CS, et al. Papillary thyroid carcinoma managed at the mayo clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26:879–85.PubMedCrossRefGoogle Scholar
  34. 34.
    Al-Saif O, Farrar WB, Bloomston M, et al. Long-term efficacy of lymph node reoperation for persistent papillary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2187–94.PubMedCrossRefGoogle Scholar
  35. 35.
    Mazzaferri EL, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore). 1977;56:171–96.CrossRefGoogle Scholar
  36. 36.
    Robenshtok E, Fish S, Bach A, et al. Suspicious cervical lymph nodes detected after thyroidectomy for papillary thyroid cancer usually remain stable over years in properly selected patients. J Clin Endocrinol Metab. 2012;97:2706–13.PubMedCrossRefGoogle Scholar
  37. 37.
    Rondeau G, Fish S, Hann LE, et al. Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. Thyroid. 2011;21:845–53.PubMedCrossRefGoogle Scholar
  38. 38.
    Nixon IJ, Ganly I, Patel S, et al. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. Surgery. 2011;150:1242–9.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Sawka AM, Straus S, Gafni A, et al. How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation? Clin Endocrinol. 2011;74:419–23.CrossRefGoogle Scholar
  40. 40.
    Sawka AM, Straus S, Rotstein L, et al. Randomized controlled trial of a computerized decision aid on adjuvant radioactive iodine treatment for patients with early-stage papillary thyroid cancer. J Clin Oncol. 2012;30:2906–11.PubMedCrossRefGoogle Scholar
  41. 41.
    Carty SE, Doherty GM, Inabnet III WB, et al. American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. Thyroid. 2012;22:395–9.PubMedCrossRefGoogle Scholar
  42. 42.
    Weinrib SL, Lane WS, Rappaport JM. Successful management of differentiated thyroid cancer in a community-based endocrine practice. Endocr Pract. 2012;18:170–8.PubMedCrossRefGoogle Scholar
  43. 43.
    Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245–62.PubMedCrossRefGoogle Scholar
  44. 44.
    Romei C, Elisei R. RET/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma. Front Endocrinol (Lausanne). 2012;3:54.Google Scholar
  45. 45.
    Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705–15.PubMedCrossRefGoogle Scholar
  46. 46.
    Schlumberger M. Target therapies for radioiodine refractory advanced thyroid tumors. J Endocrinol Invest. 2012;35(6 Suppl):40–4.PubMedGoogle Scholar
  47. 47.
    Berwick DM. The science of improvement. JAMA. 2008;299:1182–4.PubMedCrossRefGoogle Scholar
  48. 48.
    Livingston EH, McNutt RA. The hazards of evidence-based medicine assessing variations in care. JAMA. 2011;306:762–3.PubMedCrossRefGoogle Scholar

Copyright information

© K. Alok Pathak, Richard W. Nason, Janice L. Pasieka, Rehan Kazi, Raghav C. Dwivedi 2015

Authors and Affiliations

  1. 1.Division of Endocrinology and Metabolism, Department of MedicineUniversity of Calgary and Alberta Health ServicesCalgaryCanada

Personalised recommendations